ArticleThe British journal of ophthalmology2010
Mass treatment of trachoma with azithromycin 1.5% eye drops in the Republic of Cameroon: feasibility, tolerance and effectiveness.
Article in The British journal of ophthalmology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Epidemiology and control of trachoma: systematic review.Tropical medicine & international health : TM & IH · 2010Pooled it
- Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis.The British journal of ophthalmology · 2014Trial
- Comparison of Methods for Assessing Chlamydia trachomatis Transmission Intensity: A Systematic Review.The American journal of tropical medicine and hygiene · 2026Article
- Effectiveness and safety of azithromycin 1.5% eye drops for mass treatment of active trachoma in a highly endemic district in Cameroon.BMJ open ophthalmology · 2020Article
- Ocular Chlamydia trachomatis infection: elimination with mass drug administration.Expert review of anti-infective therapy · 2019Review
- The limits of medical interventions for the elimination of preventable blindness.Tropical medicine and health · 2014Article
- Prevalence of trachoma in the Far North region of Cameroon: results of a survey in 27 Health Districts.PLoS neglected tropical diseases · 2013Article
- Azithromycin reduces inflammation in a rat model of acute conjunctivitis.Molecular vision · 2013Article
- Ion-activated In Situ Gelling Ophthalmic Delivery Systems of Azithromycin.Indian journal of pharmaceutical sciences · 2011Article
- Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite) solution in the treatment of ocular infections.Clinical ophthalmology (Auckland, N.Z.) · 2011Article
- Elimination of active trachoma after two topical mass treatments with azithromycin 1.5% eye drops.PLoS neglected tropical diseases · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsAn epidemiological study carried out in 2006 indicated a high prevalence of blinding trachoma in the Kolofata Health District, Far North Region, Republic of Cameroon. As a result, the national blindness control programme of Cameroon instituted a trachoma elimination programme using the SAFE strategy.
methodsA campaign to treat the entire district population with azithromycin 1.5% eye drops was undertaken in February 2008. To measure the effectiveness of treatment on the prevalence of active trachoma, two epidemiological studies were conducted on a representative sample of children aged between 1 and 10 years. The first study was performed just prior to the treatment campaign and the second study was performed 1 year later.
resultsThe prevalence of active forms of trachoma (trachomatous inflammation--follicular (TF) + TF/trachomatous inflammation--intense (TI)) dropped from 31.5 (95% CI 26.4 to 37.5)% before treatment to 6.3 (95% CI 4.1 to 9.6)% 1 year after treatment-a reduction of nearly 80%. There were no reports of serious or systemic side effects. Tolerance was excellent and no treatment was interrupted.
conclusionMass treatment with azithromycin 1.5% eye drops is feasible, well tolerated and effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.